Gilead Sciences Inc (GILD)

76.54
+0.17(+0.22%)
  • Volume:
    253
  • Bid/Ask:
    76.17/76.59
  • Day's Range:
    76.38 - 76.54

GILD Overview

Prev. Close
76.37
Day's Range
76.38-76.54
Revenue
19.89B
Open
76.38
52 wk Range
52.23-84.73
EPS
2.66
Volume
253
Market Cap
96.3B
Dividend (Yield)
2.92
(3.50%)
Average Volume (3m)
1,688
P/E Ratio
31.38
Beta
0.468
1-Year Change
27.54%
Shares Outstanding
1,254,243,845
Next Earnings Date
-
What is your sentiment on Gilead?
or
Vote to see community's results!

Gilead Sciences Inc News

Gilead Sciences Inc Analysis

Gilead Sciences Inc Company Profile

Gilead Sciences Inc Company Profile

Employees
14400
  • Type:Equity
  • Market:Germany
  • ISIN:US3755581036
  • WKN:885823

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Read More

Analyst Price Target

Average86.26 (+3.16% Upside)
High111.00
Low63.00
Price83.62
No. of Analysts23
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      1
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • when? hahah
                0
            • Good time to accumulate.
              1
              • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                2
                • High chance to be trading above 90, good long stock
                  4
                  • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                    3